SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Miljenko Zuanic who wrote (1671)7/1/2003 2:13:09 PM
From: Biomaven  Read Replies (3) of 3044
 
J&J oncology expertise

Well they do have some oncology products - Doxil (liposomal doxorubicin) and something for hairy cell leukemia (name escapes me at present). But you are correct that they don't have much oncology development experience.

For a non-US deal this is about as best as could be expected. Developing a product like this is expensive - you need lots of trials in different indications with different combinations, so the share of development costs is significant.

Today US economic is ~40-50% of worldwide, but it may (and will) change dramatically in coming years. Global market has significant potential, imo.

That remains to be seen. There is an awful lot of temptation for many countries to just "steal" new drugs by allowing generics/knock-offs quickly, patents notwithstanding. Pharma (stupidly) initially tried to hold the line with HIV drugs - they have now retreated in disarray. Whether the HIV precedent will be followed by other areas still remains to be seen.

Canada is an interesting case. They toe the line on IP, but their strict price controls mean that they essentially get to partially free-ride on US drug development. I wouldn't be surprised to see some companies deciding to not seek approval for new drugs in Canada at all so as to avoid the re-importation problem.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News